GSK·Healthcare / Pharmaceuticals·London, United Kingdom·Founded 2000·Last verified 31 May 2026
50
out of 100
Making progressPending ReviewMixed evidence· 16 src

GSK has credible Scope 1+2 reductions and strong nature commitments, but Scope 3—93% of emissions—is stalled. The company is half the pace needed to hit its 2030 target and sits on ambiguous trade association memberships that undermine climate positioning.

The calculation

Every score shows its working.

Same formula for every company. No curve. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
67 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 67) = 60.4
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.82
Final score
Rounded. Making progress.
50 / 100
The ten questions

Where GSK is strong, and where it isn't.

Strongest on Carbon Footprint — Operations and Nature & Biodiversity Impact (8/10, 8/10). Weakest on Emissions Trajectory and Resource Use & Waste (4/10, 5/10).

Where the evidence comes from

Every document used, listed.

16 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]Self-reported
Environmental Data 2024
2024
Q1Q2Q3Q6Q7
View →
[2]Third-party verified
GSK GHG Emissions Profile (Tracenable)
Ongoing
Q1Q3
View →
[3]Self-reported
Responsible Business Performance Report 2024
2024
Q1Q9
View →
[4]Third-party verified
GSK Climate Targets (Trellis)
2024
Q2Q3Q8
View →
[5]Self-reported
GSK Climate & Energy
Ongoing
Q2Q4Q8
View →
[6]Self-reported
GSK-Schneider Electric IGNIS VPPA Partnership
2023
Q4
View →
[7]Self-reported
GSK 100% Renewable Electricity Singapore Manufacturing 2025
2024
Q4
View →
[8]Third-party verified
SBTN Company Target Tracker
Ongoing
Q5
View →
[9]Self-reported
GSK Plan for Contributing to a Nature-Positive World
2024
Q5
View →
[10]Third-party verified
TNFD Final Recommendations
2023
Q5
View →
[11]Self-reported
GSK Position on Environmental Sustainability
2024
Q6Q10
View →
[12]Self-reported
GSK Water Impact & Stewardship
Ongoing
Q7
View →
[13]Third-party verified
InfluenceMap GSK Lobbying Profile
Ongoing
Q10
View →
[14]Third-party verified
GSK Growing Profits and Reducing GHG Emissions (Sustainability Mag)
2024
Q7
View →
[15]Self-reported
GSK Pathway to Net-Zero Impact on Climate
2023
Q8
View →
[16]Third-party verified
Tracenable GSK Climate Targets
Ongoing
Q3
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

GSK in context

Where GSK sits among healthcare / pharmaceuticals peers.

Among the 11 major healthcare / pharmaceuticals brands we've scored, GSK is tied =2nd of 11, with 2 others.

=2/11
GSK's rank
46
Industry average
39
Industry low
52
Industry high
How this score has moved

GSK's score over time.

today

Score history begins 4 April 2026.

As GSK's score updates, the trajectory will appear here.

We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.

What's being contested

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About GSK

GlaxoSmithKline is a London-based pharmaceutical company specialising in prescription medicines, vaccines, and consumer healthcare. With 99,300 employees, it ranks among the top-three global pharma players. GSK faces typical sector pressures: supply-chain emissions, inhaler propellant impacts, and API manufacturing footprints.

Founded
2000
Headquarters
London, United Kingdom
Employees
~68,629
Annual revenue
~$40.1B
Company website ↗
Track GSK

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

HOW SINK STAYS INDEPENDENT

Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.